Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Eczema UK

- PMLiVE

First-ever World Chronic Hand Eczema Day launches on 5 October

The new global awareness initiative calls for greater recognition, understanding and support for people living with chronic hand eczema

- PMLiVE

LEO Pharma receives NICE approval for chronic hand eczema cream

The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

- PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

The cream is now the first treatment approved by the regulator specifically for this patient population

- PMLiVE

LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema

Anzupgo is the first topical pan-JAK inhibitor approved specifically for adults with moderate-to-severe cases

- PMLiVE

LEO Pharma’s Anzupgo cream approved by EC to treat chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

LEO Pharma receives CHMP recommendation for Anzupgo in chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema trials

About 70% of patients with severe cases of the condition report problems performing everyday activities

- PMLiVE

LEO Pharma, Allergy UK and CHE Taskforce survey reveals burden of chronic hand eczema

The painful inflammatory skin condition, hand eczema, affects up to 14% of the UK population

- PMLiVE

LEO shares positive results for delgocitinib cream in head-to-head chronic hand eczema study

Hand eczema is the most common skin disorder of the hands and one of the most common eczemas

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in long-term chronic hand eczema study

There are currently no topical treatments specifically approved for moderate-to-severe CHE

- PMLiVE

LEO Pharma reports positive results for chronic hand eczema topical treatment

Hand eczema is the most common skin disorder of the hands and one of the most common types of eczema

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links